TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

Grant

Awarded By

Total Award Amount

  • 53238.00

    • Direct Costs

  • 40952.00

    • Sponsor Award Id

    • Contributor

  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator  
  • Louis Nabors M.D.   Investigator